Soleno Therapeutics Faces Class Action Lawsuit

ClaimsFiler Reminds Investors with Losses Over $100,000 of Deadline to Join Lawsuit

Mar. 12, 2026 at 2:44am

Got story updates? Submit your updates here. ›

A class action lawsuit has been filed against Soleno Therapeutics, Inc. (SLNO) alleging the company failed to disclose material information about safety concerns with its only commercial product, DCCR, during the treatment of Prader-Willi syndrome. The lawsuit covers investors who purchased Soleno shares between March 26, 2025 and November 4, 2025, and the lead plaintiff deadline is May 5, 2026.

Why it matters

This lawsuit highlights the importance of transparency and accurate disclosures by pharmaceutical companies, especially regarding the safety and efficacy of their products. Investors rely on this information to make informed decisions, and any failure to disclose material risks could lead to significant losses.

The details

The lawsuit alleges that Soleno and its executives failed to disclose substantial evidence of potential safety concerns associated with the administration of DCCR, including indications of excessive fluid retention among clinical trial participants. This allegedly made DCCR's commercial viability and the likelihood of widespread adverse events after launch materially lower than disclosed.

  • The class period covers March 26, 2025 to November 4, 2025.
  • The lead plaintiff deadline is May 5, 2026.

The players

Soleno Therapeutics, Inc.

A biopharmaceutical company focused on the development and commercialization of therapeutic products for the treatment of rare diseases.

ClaimsFiler

A free shareholder information service that helps investors recover losses from securities class action settlements.

Got photos? Submit your photos here. ›

What’s next

The judge will decide on May 5, 2026 whether to allow the lawsuit to proceed as a class action.

The takeaway

This case highlights the importance of pharmaceutical companies being fully transparent about the safety and efficacy of their products, as investors rely on this information to make informed decisions. The lawsuit serves as a reminder that companies can be held accountable for failing to disclose material risks.